Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases | Colorectal Cancer | JAMA Oncology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Razenberg  LG, Lemmens  VE, Verwaal  VJ,  et al.  Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study.   Eur J Cancer. 2016;65:113-120. doi:10.1016/j.ejca.2016.07.002 PubMedGoogle ScholarCrossref
2.
Bushati  M, Rovers  KP, Sommariva  A,  et al.  The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).   Eur J Surg Oncol. 2018;44(12):1942-1948. doi:10.1016/j.ejso.2018.07.003 PubMedGoogle ScholarCrossref
3.
Klaver  CE, Groenen  H, Morton  DG, Laurberg  S, Bemelman  WA, Tanis  PJ; Research Committee of the European Society of Coloproctology.  Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines.   Colorectal Dis. 2017;19(3):224-236. doi:10.1111/codi.13593 PubMedGoogle ScholarCrossref
4.
Verwaal  VJ, van Ruth  S, de Bree  E,  et al.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.   J Clin Oncol. 2003;21(20):3737-3743. doi:10.1200/JCO.2003.04.187 PubMedGoogle ScholarCrossref
5.
Colorectaalcarcinoom. Landelijke richtlijn, versie: 3.0. Gastro intestinale tumoren. Published April 16, 2014. Accessed June 8, 2020. https://www.nhg.org/sites/default/files/content/nhg_org/uploads/colorectaalcarcinoom.pdf
6.
Devilee  RA, Simkens  GA, van Oudheusden  TR,  et al.  Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.   Ann Surg Oncol. 2016;23(9):2841-2848. doi:10.1245/s10434-016-5214-3 PubMedGoogle ScholarCrossref
7.
Rovers  KP, Simkens  GA, Punt  CJ, van Dieren  S, Tanis  PJ, de Hingh  IH.  Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? a critical systematic review.   Crit Rev Oncol Hematol. 2017;114:53-62. doi:10.1016/j.critrevonc.2017.03.028 PubMedGoogle ScholarCrossref
8.
Kuijpers  AM, Mirck  B, Aalbers  AG,  et al.  Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol.   Ann Surg Oncol. 2013;20(13):4224-4230. doi:10.1245/s10434-013-3145-9 PubMedGoogle ScholarCrossref
9.
Rovers  KP, Bakkers  C, Simkens  GAAM,  et al; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).  Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).   BMC Cancer. 2019;19(1):390. doi:10.1186/s12885-019-5545-0 PubMedGoogle ScholarCrossref
10.
Giobbie-Hurder  A, Gelber  RD, Regan  MM.  Challenges of guarantee-time bias.   J Clin Oncol. 2013;31(23):2963-2969. doi:10.1200/JCO.2013.49.5283 PubMedGoogle ScholarCrossref
11.
Schmoll  HJ, Van Cutsem  E, Stein  A,  et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making.   Ann Oncol. 2012;23(10):2479-2516. doi:10.1093/annonc/mds236 PubMedGoogle ScholarCrossref
12.
Allegra  CJ, Yothers  G, O’Connell  MJ,  et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.   J Clin Oncol. 2011;29(1):11-16. doi:10.1200/JCO.2010.30.0855 PubMedGoogle ScholarCrossref
13.
de Gramont  A, Van Cutsem  E, Schmoll  HJ,  et al.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.   Lancet Oncol. 2012;13(12):1225-1233. doi:10.1016/S1470-2045(12)70509-0 PubMedGoogle ScholarCrossref
14.
Alberts  SR, Sargent  DJ, Nair  S,  et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial.   JAMA. 2012;307(13):1383-1393. doi:10.1001/jama.2012.385 PubMedGoogle ScholarCrossref
15.
Taieb  J, Tabernero  J, Mini  E,  et al; PETACC-8 Study Investigators.  Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.   Lancet Oncol. 2014;15(8):862-873. doi:10.1016/S1470-2045(14)70227-X PubMedGoogle ScholarCrossref
16.
Kerr  RS, Love  S, Segelov  E,  et al.  Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.   Lancet Oncol. 2016;17(11):1543-1557. doi:10.1016/S1470-2045(16)30172-3 PubMedGoogle ScholarCrossref
17.
Rosenbaum  PR, Rubin  DB.  The central role of the propensity score in observational studies for causal effects.   Biometrika. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41 Google ScholarCrossref
18.
Austin  PC.  Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations.   Biom J. 2009;51(1):171-184. doi:10.1002/bimj.200810488 PubMedGoogle ScholarCrossref
19.
Austin  PC.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.   Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697 PubMedGoogle ScholarCrossref
20.
Sterne  JA, White  IR, Carlin  JB,  et al.  Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.   BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393 PubMedGoogle ScholarCrossref
21.
Wang  R, Lagakos  SW, Ware  JH, Hunter  DJ, Drazen  JM.  Statistics in medicine—reporting of subgroup analyses in clinical trials.   N Engl J Med. 2007;357(21):2189-2194. doi:10.1056/NEJMsr077003 PubMedGoogle ScholarCrossref
22.
Simkens  GA, van Oudheusden  TR, Luyer  MD,  et al.  Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis.   Ann Surg Oncol. 2015;22(8):2656-2662. doi:10.1245/s10434-014-4297-y PubMedGoogle ScholarCrossref
23.
Lin  DY, Psaty  BM, Kronmal  RA.  Assessing the sensitivity of regression results to unmeasured confounders in observational studies.   Biometrics. 1998;54(3):948-963. doi:10.2307/2533848 PubMedGoogle ScholarCrossref
24.
van Eden  WJ, Kok  NF, Jóźwiak  K,  et al.  Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.   Dis Colon Rectum. 2017;60(5):477-487. doi:10.1097/DCR.0000000000000774 PubMedGoogle ScholarCrossref
25.
van Eden  WJ, Kok  NFM, Woensdregt  K, Huitema  ADR, Boot  H, Aalbers  AGJ.  Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.   Eur J Surg Oncol. 2018;44(2):220-227. doi:10.1016/j.ejso.2017.10.216 PubMedGoogle ScholarCrossref
26.
Culliford  AT  IV, Brooks  AD, Sharma  S,  et al.  Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.   Ann Surg Oncol. 2001;8(10):787-795. doi:10.1007/s10434-001-0787-9 PubMedGoogle ScholarCrossref
27.
Glehen  O, Cotte  E, Schreiber  V, Sayag-Beaujard  AC, Vignal  J, Gilly  FN.  Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin.   Br J Surg. 2004;91(6):747-754. doi:10.1002/bjs.4473 PubMedGoogle ScholarCrossref
28.
Glehen  O, Kwiatkowski  F, Sugarbaker  PH,  et al.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.   J Clin Oncol. 2004;22(16):3284-3292. doi:10.1200/JCO.2004.10.012 PubMedGoogle ScholarCrossref
29.
Gilly  FN; International Registry of Colorectal Carcinomatosis.  Phase II studies: international registry of colorectal carcinomatosis.   Eur J Surg Oncol. 2006;32(6):648-654. doi:10.1016/j.ejso.2006.03.030 PubMedGoogle ScholarCrossref
30.
Elias  D, Gilly  F, Boutitie  F,  et al.  Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.   J Clin Oncol. 2010;28(1):63-68. doi:10.1200/JCO.2009.23.9285 PubMedGoogle ScholarCrossref
31.
Passot  G, Vaudoyer  D, Cotte  E,  et al.  Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis.   Ann Surg. 2012;256(1):125-129. doi:10.1097/SLA.0b013e318255486a PubMedGoogle ScholarCrossref
32.
Cashin  PH, Graf  W, Nygren  P, Mahteme  H.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study.   Eur J Surg Oncol. 2012;38(6):509-515. doi:10.1016/j.ejso.2012.03.001 PubMedGoogle ScholarCrossref
33.
Maggiori  L, Goéré  D, Viana  B,  et al.  Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? a case-control study.   Ann Surg. 2013;258(1):116-121. doi:10.1097/SLA.0b013e3182778089 PubMedGoogle ScholarCrossref
34.
Ung  L, Chua  TC, David L  M.  Peritoneal metastases of lower gastrointestinal tract origin: a comparative study of patient outcomes following cytoreduction and intraperitoneal chemotherapy.   J Cancer Res Clin Oncol. 2013;139(11):1899-1908. doi:10.1007/s00432-013-1517-y PubMedGoogle ScholarCrossref
35.
Nikolic  S, Dzodic  R, Zegarac  M,  et al.  Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.   J BUON. 2014;19(1):66-74. doi:10.1016/j.ejso.2014.08.415 PubMedGoogle Scholar
36.
Ceelen  W, Van Nieuwenhove  Y, Putte  DV, Pattyn  P.  Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.   Ann Surg Oncol. 2014;21(9):3023-3028. doi:10.1245/s10434-014-3713-7 PubMedGoogle ScholarCrossref
37.
Maillet  M, Glehen  O, Lambert  J,  et al; BIG-RENAPE Working Group.  Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study.   Ann Surg Oncol. 2016;23(3):863-869. doi:10.1245/s10434-015-4914-4 PubMedGoogle ScholarCrossref
38.
Lemmens  VE, Klaver  YL, Verwaal  VJ, Rutten  HJ, Coebergh  JW, de Hingh  IH.  Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study.   Int J Cancer. 2011;128(11):2717-2725. doi:10.1002/ijc.25596 PubMedGoogle ScholarCrossref
39.
van Oudheusden  TR, Nienhuijs  SW, Luyer  MD,  et al.  Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: a systematic review.   Eur J Surg Oncol. 2015;41(10):1269-1277. doi:10.1016/j.ejso.2015.05.018 PubMedGoogle ScholarCrossref
40.
van Gestel  YR, de Hingh  IH, van Herk-Sukel  MP,  et al.  Patterns of metachronous metastases after curative treatment of colorectal cancer.   Cancer Epidemiol. 2014;38(4):448-454. doi:10.1016/j.canep.2014.04.004 PubMedGoogle ScholarCrossref
41.
Liberale  G, Vankerckhove  S, Caldon  MG,  et al; Group R&D for the Clinical Application of Fluorescence Imaging of the Jules Bordetʼs Institute.  Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: a pilot study.   Ann Surg. 2016;264(6):1110-1115. doi:10.1097/SLA.0000000000001618 PubMedGoogle ScholarCrossref
42.
Harlaar  NJ, Koller  M, de Jongh  SJ,  et al.  Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study.   Lancet Gastroenterol Hepatol. 2016;1(4):283-290. doi:10.1016/S2468-1253(16)30082-6 PubMedGoogle ScholarCrossref
43.
Boogerd  LSF, Hoogstins  CES, Schaap  DP,  et al.  Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study.   Lancet Gastroenterol Hepatol. 2018;3(3):181-191. doi:10.1016/S2468-1253(17)30395-3 PubMedGoogle ScholarCrossref
44.
Moertel  CG, Fleming  TR, Macdonald  JS,  et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.   N Engl J Med. 1990;322(6):352-358. doi:10.1056/NEJM199002083220602 PubMedGoogle ScholarCrossref
45.
Oettle  H, Neuhaus  P, Hochhaus  A,  et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.   JAMA. 2013;310(14):1473-1481. doi:10.1001/jama.2013.279201 PubMedGoogle ScholarCrossref
46.
Noh  SH, Park  SR, Yang  HK,  et al; CLASSIC Trial Investigators.  Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.   Lancet Oncol. 2014;15(12):1389-1396. doi:10.1016/S1470-2045(14)70473-5 PubMedGoogle ScholarCrossref
47.
Primrose  JN, Fox  RP, Palmer  DH,  et al; BILCAP Study Group.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.   Lancet Oncol. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X PubMedGoogle ScholarCrossref
48.
Mitry  E, Fields  AL, Bleiberg  H,  et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.   J Clin Oncol. 2008;26(30):4906-4911. doi:10.1200/JCO.2008.17.3781 PubMedGoogle ScholarCrossref
49.
Snoeren  N, van Hillegersberg  R, Schouten  SB,  et al; Hepatica Study Group.  Randomized phase III study to assess efficacy and safety of adjuvant CAPOX with or without bevacizumab in patients after resection of colorectal liver metastases: HEPATICA study.   Neoplasia. 2017;19(2):93-99. doi:10.1016/j.neo.2016.08.010 PubMedGoogle ScholarCrossref
50.
Cunningham  D, Allum  WH, Stenning  SP,  et al; MAGIC Trial Participants.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.   N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531 PubMedGoogle ScholarCrossref
51.
van Hagen  P, Hulshof  MC, van Lanschot  JJ,  et al; CROSS Group.  Preoperative chemoradiotherapy for esophageal or junctional cancer.   N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMoa1112088 PubMedGoogle ScholarCrossref
52.
Razenberg  LG, van Gestel  YR, Creemers  GJ, Verwaal  VJ, Lemmens  VE, de Hingh  IH.  Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.   Eur J Surg Oncol. 2015;41(4):466-471. doi:10.1016/j.ejso.2015.01.018 PubMedGoogle ScholarCrossref
53.
Jacquet  P, Sugarbaker  PH.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.   Cancer Treat Res. 1996;82:359-374. doi:10.1007/978-1-4613-1247-5_23 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    July 16, 2020

    Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases

    Author Affiliations
    • 1Department of Surgery, Catharina Cancer Institute, Eindhoven, the Netherlands
    • 2Department of Research, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands
    • 3Department of Medical Oncology, Catharina Cancer Institute, Eindhoven, the Netherlands
    • 4Department of Surgery, University Medical Centre Groningen, Groningen, the Netherlands
    • 5Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
    • 6Department of Public Health, Erasmus University Medical Centre, Rotterdam, the Netherlands
    • 7Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands
    • 8GROW-School for Oncology and Development Biology, Maastricht University, Maastricht, the Netherlands
    JAMA Oncol. 2020;6(8):e202701. doi:10.1001/jamaoncol.2020.2701
    Key Points

    Question  Is adjuvant systemic chemotherapy associated with improved overall survival compared with active surveillance in patients undergoing up-front resection of isolated synchronous colorectal peritoneal metastases?

    Findings  In this Dutch nationwide propensity score–matched cohort study including 393 patients, adjuvant systemic chemotherapy was associated with improved overall survival (median, 39 months) compared with active surveillance (median, 25 months). This difference in survival rates was statistically significant.

    Meaning  In this study, adjuvant systemic chemotherapy was associated with improved overall survival following up-front resection of isolated synchronous colorectal peritoneal metastases; however, randomized trials are needed to address the influence of potential residual confounding and allocation bias on this association.

    Abstract

    Importance  To date, there are no data on the value of adjuvant systemic chemotherapy following up-front resection of isolated synchronous colorectal peritoneal metastases.

    Objective  To assess the association between adjuvant systemic chemotherapy and overall survival following up-front resection of isolated synchronous colorectal peritoneal metastases.

    Design, Setting, and Participants  In this population-based, observational cohort study using nationwide data from the Netherlands Cancer Registry (diagnoses between January 1, 2005, and December 31, 2017; follow-up until January 31, 2019), 393 patients with isolated synchronous colorectal peritoneal metastases who were alive 3 months after up-front complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy were included. Patients allocated to the adjuvant systemic chemotherapy group were matched (1:1) with those allocated to the active surveillance group by propensity scores based on patient-, tumor-, and treatment-level covariates.

    Exposures  Adjuvant systemic chemotherapy, defined as systemic chemotherapy without targeted therapy, starting within 3 months postoperatively.

    Main Outcomes and Measures  Overall survival was compared between matched groups using Cox proportional hazards regression analysis adjusted for residual imbalance. A landmark analysis was performed by excluding patients who died within 6 months postoperatively. A sensitivity analysis was performed to adjust for unmeasured confounding by major postoperative morbidity.

    Results  Of 393 patients (mean [SD] age, 61 [10] years; 181 [46%] men), 172 patients (44%) were allocated to the adjuvant systemic chemotherapy group. After propensity score matching of 142 patients in the adjuvant systemic chemotherapy group with 142 patients in the active surveillance group, adjuvant systemic chemotherapy was associated with improved overall survival compared with active surveillance (median, 39.2 [interquartile range, 21.1-111.1] months vs 24.8 [interquartile range, 15.0-58.4] months; adjusted hazard ratio [aHR], 0.66; 95% CI, 0.49-0.88; P = .006), which remained consistent after excluding patients who died within 6 months postoperatively (aHR, 0.68; 95% CI, 0.50-0.93; P = .02) and after adjustment for major postoperative morbidity (aHR, 0.71; 95% CI, 0.53-0.95).

    Conclusions and Relevance  Findings of this study suggest that in patients undergoing up-front resection of isolated synchronous colorectal peritoneal metastases, adjuvant systemic chemotherapy appeared to be associated with improved overall survival. Although randomized trials are needed to address the influence of potential residual confounding and allocation bias on this association, results of this study may be used for clinical decision-making in this patient group for whom no data are available.

    ×